Reshma Kewalramani - 22 Jan 2026 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
CEO & President, Director
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
22 Jan 2026
Net transactions value
$0
Form type
4
Filing time
26 Jan 2026, 16:25:45 UTC
Previous filing
07 Aug 2025
Next filing
12 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kewalramani Reshma CEO & President, Director C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON /s/ Christiana Stevenson, Attorney-in-Fact 26 Jan 2026 0001735944

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Award $0 +26,972 +23% $0.000000 142,940 22 Jan 2026 Direct F1
transaction VRTX Common Stock Award $0 +11,885 +8.3% $0.000000 154,825 22 Jan 2026 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026.
F2 Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.